Literature DB >> 35915245

Targeting the androgen receptor to enhance NK cell killing efficacy in bladder cancer by modulating ADAR2/circ_0001005/PD-L1 signaling.

Qing Liu1,2, Bosen You1,2, Jialin Meng2, Chi-Ping Huang3, Guanglu Dong1, Ronghao Wang2, Fuju Chou2, Shan Gao1, Chawnshang Chang2,3, Shuyuan Yeh4, Wanhai Xu5.   

Abstract

Although androgen receptor (AR) can influence bladder cancer (BCa) initiation and progression, its impact on tumor immune escape remains unclear. Here, we found that targeting AR could enhance natural killer (NK) cell tumor-killing efficacy by decreasing PD-L1 expression. Both antiandrogen treatment and AR knockdown effectively reduced membrane PD-LI expression to facilitate NK cell-mediated BCa cell killing by downregulating circ_0001005. Mechanistically, AR upregulated circRNA circ_0001005 expression via the RNA-editing gene ADAR2. circ_0001005 competitively sponged the miRNA miR-200a-3p to promote PD-L1 expression. A preclinical BCa xenograft mouse model further confirmed this newly identified signaling using the small molecule circ_0001005-shRNA to improve NK cell killing of BCa tumor cells. Collectively, these results suggest that targeting the newly identified ADAR2/circ_0001005/miR-200a-3p/PD-L1 pathway to impact antitumor immunity may suppress progression and boost immunotherapeutic efficacy in BCa.
© 2022. The Author(s).

Entities:  

Year:  2022        PMID: 35915245     DOI: 10.1038/s41417-022-00506-w

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.854


  50 in total

1.  PD-1 expression on natural killer cells and CD8(+) T cells during chronic HIV-1 infection.

Authors:  Sonia Norris; Adam Coleman; Leticia Kuri-Cervantes; Mark Bower; Mark Nelson; Martin R Goodier
Journal:  Viral Immunol       Date:  2012-06-28       Impact factor: 2.257

Review 2.  Immune checkpoint inhibitors for metastatic bladder cancer.

Authors:  Francesco Massari; Vincenzo Di Nunno; Marta Cubelli; Matteo Santoni; Michelangelo Fiorentino; Rodolfo Montironi; Liang Cheng; Anto Lopez-Beltran; Nicola Battelli; Andrea Ardizzoni
Journal:  Cancer Treat Rev       Date:  2018-01-31       Impact factor: 12.111

Review 3.  The blockade of immune checkpoints in cancer immunotherapy.

Authors:  Drew M Pardoll
Journal:  Nat Rev Cancer       Date:  2012-03-22       Impact factor: 60.716

Review 4.  Gene regulation in the immune system by long noncoding RNAs.

Authors:  Y Grace Chen; Ansuman T Satpathy; Howard Y Chang
Journal:  Nat Immunol       Date:  2017-08-22       Impact factor: 25.606

Review 5.  The emerging role of the androgen receptor in bladder cancer.

Authors:  Alan P Lombard; Maria Mudryj
Journal:  Endocr Relat Cancer       Date:  2015-07-30       Impact factor: 5.678

6.  Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.

Authors:  Arjun V Balar; Matthew D Galsky; Jonathan E Rosenberg; Thomas Powles; Daniel P Petrylak; Joaquim Bellmunt; Yohann Loriot; Andrea Necchi; Jean Hoffman-Censits; Jose Luis Perez-Gracia; Nancy A Dawson; Michiel S van der Heijden; Robert Dreicer; Sandy Srinivas; Margitta M Retz; Richard W Joseph; Alexandra Drakaki; Ulka N Vaishampayan; Srikala S Sridhar; David I Quinn; Ignacio Durán; David R Shaffer; Bernhard J Eigl; Petros D Grivas; Evan Y Yu; Shi Li; Edward E Kadel; Zachary Boyd; Richard Bourgon; Priti S Hegde; Sanjeev Mariathasan; AnnChristine Thåström; Oyewale O Abidoye; Gregg D Fine; Dean F Bajorin
Journal:  Lancet       Date:  2016-12-08       Impact factor: 79.321

Review 7.  Gender and Bladder Cancer: A Collaborative Review of Etiology, Biology, and Outcomes.

Authors:  Jakub Dobruch; Siamak Daneshmand; Margit Fisch; Yair Lotan; Aidan P Noon; Matthew J Resnick; Shahrokh F Shariat; Alexandre R Zlotta; Stephen A Boorjian
Journal:  Eur Urol       Date:  2015-09-04       Impact factor: 20.096

Review 8.  Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy.

Authors:  Suzanne L Topalian; Janis M Taube; Robert A Anders; Drew M Pardoll
Journal:  Nat Rev Cancer       Date:  2016-04-15       Impact factor: 60.716

9.  Androgen receptor activity modulates responses to cisplatin treatment in bladder cancer.

Authors:  Eiji Kashiwagi; Hiroki Ide; Satoshi Inoue; Takashi Kawahara; Yichun Zheng; Leonardo O Reis; Alexander S Baras; Hiroshi Miyamoto
Journal:  Oncotarget       Date:  2016-08-02

10.  Increased expression of programmed cell death protein 1 on NK cells inhibits NK-cell-mediated anti-tumor function and indicates poor prognosis in digestive cancers.

Authors:  Y Liu; Y Cheng; Y Xu; Z Wang; X Du; C Li; J Peng; L Gao; X Liang; C Ma
Journal:  Oncogene       Date:  2017-07-10       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.